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ABSTRACT  60 
 61 
Multiple studies have shown that dermoscopy increases the sensitivity and specificity for the 62 
detection of skin cancers compared to naked-eye examination. Dermoscopy can also lead to the 63 
detection of thinner and smaller cancers. Furthermore, dermoscopy leads to more precise 64 
selection of lesions requiring excision. In essence, dermoscopy helps clinicians differentiate 65 
benign from malignant lesions through the presence or absence of specific dermoscopic 66 
structures. Therefore, since most dermoscopic structures have direct histopathologic correlates, 67 
dermoscopy can allow the prediction of certain histologic findings present in skin cancers, thus 68 
helping select management and treatment options for select types of skin cancers.  Visualizing 69 
dermoscopic structures in the ex vivo specimens can also be beneficial. It can improve the 70 
histologic diagnostic accuracy by targeted step-sectioning in areas of  concern, which can be 71 
marked by the clinician before sending the specimen to the pathologist, or by the pathologist on 72 
the excised specimen in the laboratory. In addition, ex vivo dermoscopy can also be used to 73 
select tumor areas with genetic importance since some dermoscopic structures have been related 74 
to mutations with theragnostic relevance. In the second article of this continuing medical 75 
education series we review the impact of dermoscopy on the diagnostic accuracy of skin cancer, 76 
how can dermoscopy affect the histopathologic examination, and which dermoscopic features 77 
may be more relevant in terms of histological and genetic prediction.  78 
  79 
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INTRODUCTION 80 
 Dermoscopy has shown to increase the sensitivity for detecting skin cancers compared to 81 
naked-eye examination (NEE), and this increase is not occurring at the expense of a lower  82 
specificity.1 In essence, dermoscopy leads to the biopsy of a more selective group of lesions and 83 
this is reflected in a reduction in the number of benign lesions biopsied for every skin cancer 84 
found.1-3 Dermoscopy helps distinguishing benign from malignant lesions by revealing structures 85 
and patterns not visible with the NEE. Since these structures have direct histopathologic 86 
correlates (continuing medical education [CME] part 1), clinicians can more precisely predict 87 
histologic findings. In addition, visualizing dermoscopic structures in the ex vivo biopsy 88 
specimens can also be beneficial. This is particularly relevant when grossing skin cancers such as 89 
melanomas since there may be variability in tumor thickness across the tumoral area. In addition, 90 
some melanomas may be focally present within a nevus and in this scenario the correct diagnosis 91 
will be contingent upon sectioning the tissue in the appropriate plane. In fact, dermoscopy can 92 
improve grossing since only about 0.1% of a 4 mm specimen actually gets presented to the 93 
pathologist on a glass slide.4  94 
 95 
Multiple methods aimed at targeting the areas to step-section have been proposed by 96 
clinicians and pathologists. Clinicians can provide descriptions or pictures of the lesion to the 97 
pathologist, or can mark the area directly on the specimenby suture, ink or punch scoring before 98 
sending it to the laboratory.5-9 4 Conversely, this marking can also be done in the laboratory by 99 
the pathologist or histo-technician since most dermoscopic structures can be identified on 100 
formalin fixed tissue,10 in a process called ex vivo dermoscopy (EVD) (figure 1).11  101 
Dermoscopy-guided sectioning may reduce the number of slides necessary to render a correct 102 
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diagnosis and this can impact cost containment in a positive manner. In addition, studies have 103 
shown that select dermoscopic structures can predict a higher degree of atypia, genetic 104 
mutations, or certain histologic subtypes when evaluating lesions suspicious for skin cancers.4, 12-105 
15
 Therefore, dermoscopy-guided sectioning offers an exciting opportunity for research by 106 
selecting different samples for biobanks, and allowing the detection of genetic mutations with 107 
theragnostic implications. 108 
 109 
  110 
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USE OF DERMOSCOPY TO IMPROVE THE CLINICAL DIAGNOSTIC ACCURACY 111 
FOR SKIN CANCER DETECTION 112 
Key notes 113 
• Dermoscopy increases the sensitivity for skin cancer detection and lowers the benign to 114 
malignant biopsy ratio. 115 
• Limitations of dermoscopy include the learning curve and the occasional nonconformity 116 
of skin cancers to defined diagnostic criteria. 117 
• Ultimately, the decision to biopsy a lesion requires the integration of multiple parameters 118 
including clinical information, morphologic analysis, and comparative and pattern 119 
analysis. 120 
 121 
Advantages of dermoscopy 122 
Since melanoma can become an aggressive tumor, maintaining a high sensitivity remains 123 
paramount and lesions clinically suspicious for malignancy should be excised. Some have 124 
suggested that it is justifiable to biopsy over 100 benign lesions in order to detect a single 125 
melanoma at an early stage.16 This aggressive approach with the aim of maintaining a high 126 
sensitivity, fails to acknowledge the harmful consequences from having such a low specificity 127 
(i.e., scarring, pain, would infection, patient fear/anxiety) and driving up costs of health care.  128 
 129 
Multiple meta-analyses have shown that dermoscopy improves user diagnostic accuracy 130 
for diagnosing skin cancers.1, 17, 18 In fact, dermoscopy enables the detection of melanomas with 131 
a sensitivity that is significantly higher than the NEE (90% vs 71%).1 This is in part due to the 132 
misclassification of approximately 40% of melanomas as benign when using only the clinical 133 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
ABCDE rule.19 Dermoscopy also has a higher specificity compared to NEE (90% vs 81%).1 This 134 
results in fewer biopsies/excisions necessary to find a skin cancer (4-5:1 with dermoscopy vs 12-135 
15:1 with NEE alone2, 24). One would think that reducing the benign to malignant biopsy ratio 136 
(BMR) may be at the cost of detecting more advanced cancers. However, dermoscopy in fact 137 
detects skin cancers at an earlier stage compared to NEE.3, 25-28 Thus, because dermoscopy has a 138 
high sensitivity for diagnosing skin cancers, it decreases the number of unnecessary biopsies, it 139 
identifies cancers earlier, and it results in a cost-effective cancer screening strategy.29, 30  140 
 141 
Limitations of dermoscopy 142 
As with any diagnostic tool, dermoscopy requires training During the training and 143 
learning phase the clinicians tend to increase their sensitivity but lower their specificity. In fact, 144 
during the first year after learning dermoscopy, generally the BMR increases.18, 34 However, after 145 
gaining some experience, the clinician’s specificity also increases and this eventuates into an 146 
improved BMR compared to pre-dermoscopy use and NEE.34  147 
 148 
It is important to highlight that dermoscopy should not be used without clinical history 149 
and clinical findings. The history and clinical features such as degree of firmness, and elevation 150 
are important pieces of information that need to be placed in context with the dermoscopic 151 
morphology. The final decision on whether to biopsy or not requires the integration of analytical 152 
data (i.e., clinical ABCDE, dermoscopic features), comparative reasoning (i.e., is the lesion new 153 
or changing compared to previous images), differential recognition (i.e., ugly duckling, single vs 154 
multiple lesions), pattern recognition or gestalt, patient history (i.e., age, gender, comorbidities), 155 
and “gut feeling”.35 This is important to appreciate since some skin cancers may lack specific 156 
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dermoscopic features, making them impossible to diagnose based purely on dermoscopic 157 
morphology. In addition, dermoscopic features and patterns may vary based on age, skin type, 158 
location, and extent of sun damage and this information also needs to be placed in context when 159 
interpreting dermoscopy. Despite these limitations, there is not a single study that has shown that 160 
dermoscopists perform worse as compared to non-dermoscopists.  161 
 162 
 163 
USING DERMOSCOPY TO IMPROVE HISTOLOGICAL ANALYSIS 164 
Key notes 165 
• Dermoscopy can inform the pathologist on how best to process and section the tissue. 166 
This dermoscopic information can be provided to the pathologist via dermoscopic images 167 
or descriptions, and by the clinician marking the area of most concern before submitting 168 
the specimen to the laboratory. 169 
• Since most dermoscopic features are visible after formalin fixation, dermoscopy can be 170 
used to guide step sectioning in the laboratory in a technique called ex vivo dermoscopy. 171 
• Marking the specimen in vivo or ex vivo using dermoscopy improves the histological 172 
diagnostic accuracy and potentially reduces the costs of histologic processing. 173 
 174 
The role of the clinician  175 
Dermoscopy is widely used by dermatologists and non-dermatologists,31, 41 who are 176 
increasingly sampling a higher proportion of complex and histological equivocal lesions. For 177 
such lesions the clinical information may greatly help the pathologist in rendering the most 178 
accurate diagnosis. Clinicians can provide pathologists with clinical images, dermoscopic 179 
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images, dermoscopic descriptions, or may mark areas of interest before sending the specimen to 180 
the pathology laboratory.6-8  However, dermoscopy images and descriptions are only useful if 181 
sent to dermatopathologists who understand the importance of clinical-dermoscopy-182 
histopathology correlations and who have acquired at least some knowledge about dermoscopy 183 
and their association with disease. For specimens sent to dermatopathologists who have little or 184 
no knowledge about dermoscopy, the clinician may want to consider marking the area of interest 185 
or bisecting the specimen in the plane of interest so as to insure that the area of clinical concern 186 
does in fact get sectioned. While these strategies have shown to improve the diagnostic accuracy 187 
of pathologists, currently they are rarely employed outside specialized cancer centers.42 As the 188 
importance of clinical-dermoscopy-pathology correlation becomes more widely appreciated, it is 189 
likely that the aforementioned methods will be more widely adopted.  190 
 191 
Benefits of including dermoscopic information and/or images as part of the pathology 192 
requisition form: 193 
As part of the pathology request form, an increasing number of clinicians are starting to 194 
add drawings, pictures or dermoscopic descriptors to the clinical information of lesions being 195 
submitted. This added information improves the diagnostic accuracy of histological analysis43 as 196 
it directs the pathologic analysis and elicits a more careful examination of sections.44 Ideally, 197 
pathologists should have access to clinical and dermoscopic images of complex melanocytic 198 
lesions in order to visually assess the areas of highest concern and determine orientation of step 199 
sectioning. Contrary to a common misconception, access to additional information prior to 200 
histopathologic review is not associated with diagnostic bias and actually may be helpful,5 even 201 
increasing the histologic interobserver agreement.9 202 
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 203 
 Advantages for the pathologist of highlighting the area/s of clinical concern within excised 204 
lesion: 205 
Before sending a specimen, clinicians have the opportunity to mark areas that display 206 
dermoscopic features that may have significance for the pathologist during the histopathological 207 
analysis. Clinicians can mark the specimen in multiple ways including using ink or nail varnish, 208 
placing a suture in the area of interest, scoring the area with a scalpel or a micropunch, or 209 
bisecting the specimen themselves.4, 6-8 Irrespective of the method, the mark left by the clinician 210 
may help identify small select areas that may have been otherwise missed during the 211 
conventional step sectioning procedure (figure 2).4 However, clinicians must be cautioned not to 212 
damage the scored tissue to such an extent as to compromise histopathologic analysis.4  213 
 214 
The role of the pathologist  215 
Dermatopathologists routinely evaluate full-thickness skin sections in the vertical plane 216 
of a small percentage of the entire specimens volume, whereas dermoscopists evaluate the entire 217 
lesion in the horizontal plane but only to a maximum depth of the papillary dermis.45 Therefore, 218 
both techniques are complementary and can be used in the laboratory to improve grossing. 219 
Towards this goal, pathologists need to acquire knowledge of the dermoscopy terminology and 220 
histology correlates, and dermoscopists need to acquire knowledge of histopathology (CME part 221 
1).   222 
 223 
Benefits of examining the ex vivo dermoscopy before step-sectioning 224 
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Dermoscopy is a diagnostic tool meant to be used in vivo directly on the patient’s skin. 225 
However, dermoscopy can also be used on excised tissue because most dermoscopic features are 226 
visible even after formalin fixation.10, 11 This technique is called ex vivo dermoscopy (EVD),11 227 
and can help guide specimen grossing. As previously indicated (CME part 1), the colors and 228 
structures seen on dermoscopy have histopathologic correlates, which may have diagnostic and 229 
prognostic significance. For example, when grossing a pigmented melanoma, sections containing 230 
scarlike depigmentation or peppering on dermoscopy may underestimate the tumor thickness as 231 
they correspond to regression. Conversely, blue-gray areas indicate deep dermal melanocytes 232 
and thus this area will likely provide the most accurate indication of maximum tumor 233 
thickness.46, 47 EVD can also be useful to the pathologist when little or no clinical information is 234 
provided in the requisition form. In this scenario, reviewing the submitted specimen with a 235 
dermatoscope before grossing the lesion has shown to improve the diagnosis of ambiguous 236 
melanocytic and non-melanocytic lesions.48-50 Haspeslagh et al. found that EVD improved the 237 
detection of positive margins in keratinocyte carcinomas from ~8% to ~13%. In melanocytic 238 
lesions, this technique lead to the detection of a higher degree of atypia, ulceration, and higher 239 
mitotic rates.50 In addition, Cabete et al. found that EVD elicited a change in the final diagnosis 240 
in ~14% of the studied cases, and EVD helped in the detection of melanomas missed with 241 
conventional step sectioning and improved the staging of melanomas.49 In addition, EVD has 242 
shown to decrease the diagnostic turnaround time50, a finding that indicates EVD can potentially 243 
optimize step-sectioning and reduce the costs of histopathologic processing. 244 
 245 
EVD has some differences compared to conventional dermoscopy. While EVD clearly 246 
identifies structures containing pigment such as network, globules or streaks,10, 11 some structures 247 
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are less conspicuous. In EVD, there are more structureless areas and a decrease in the focus 248 
sharpness.10, 11, 48 Furthermore, after fixation some colors may appear enhanced (blue, brown, 249 
white), while others colors such as red may be less conspicuous due to a poor or absent 250 
visualization of blood vessels and degradation of hemoglobin after excision.10, 11, 51 This makes 251 
EVD challenging in amelanotic lesions. Another way to evaluate the dermoscopic features of 252 
excised specimens can be through photographs of the dermoscopic image. A dermatoscope can 253 
be attached to a camera50 or simply attached to a smartphone (figure 1). This results in a cleaner 254 
and safer method to evaluate lesions, and provides an easy way to document the findings for 255 
future clinical, research, or academic purposes. EVD has a more important role in medium-to-256 
large complex pigmented lesions or in wide excisions containing focal pigmented areas than on 257 
tiny specimens.11 Regarding larger lesions, the same way clinicians may mark the area of 258 
concern, pathologists or histo-technicians can also mark the specimen in order to identify a given 259 
area under the microscope.52 In fact, it has been suggested that the marking of the specimen 260 
should be performed in the laboratory to minimize tissue loss or destruction.50, 52  261 
 262 
In the era of targeted therapies, EVD also has exciting potential in research. Several 263 
dermoscopic structures have been correlated with select genetic mutations (see below). 264 
Therefore, EVD can be used as a tool to gross specimens and select areas which can later be 265 
tested for mutations, or stored for future studies in biobanks. The dermoscopic image could then 266 
serve as an en face map of the clones present within a given lesion.53  267 
 268 
  269 
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DERMOSCOPIC FEATURES WITH SPECIAL RELEVANCE FOR THE CLINICIAN 270 
AND THE PATHOLOGIST 271 
Key points 272 
• Several dermoscopic features are highly specific for melanoma and are called melanoma-273 
specific structures. 274 
• Select dermoscopic findings can predict the presence of aggressive melanomas as well as 275 
the presence of genetic mutations. 276 
• Dermoscopy can predict the indolent vs. aggressive subtypes of keratinocyte carcinomas 277 
and may help triage lesions. 278 
• Although relatively specific, the structures suggestive for melanocytic lesions can be 279 
encountered in non-melanocytic lesions and this may explain the discordance between 280 
the clinical/dermoscopic and the final histopathological diagnosis of many cases. 281 
 282 
Dermoscopic features with special relevance present in melanocytic lesions  283 
 284 
1. Melanoma-specific structures 285 
Several dermoscopic features have been associated with a high odds ratio for melanoma 286 
when encountered in melanocytic lesions. These structures are collectively known as melanoma-287 
specific structures. They include atypical pigment network, angulated lines, irregular streaks, 288 
negative pigment network, shiny white streaks, irregular dots and globules, irregular blotch, 289 
blue-white veil, regression structures (peppering and scarlike depigmentation), and 290 
polymorphous vessels. These features, which have well-established histopathological correlates 291 
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(CME part 1), are summarized in table I and shown in figure 3. We have described these features 292 
according to the 2016 International Dermoscopy Consensus on dermoscopic terminology.54, 55 293 
 294 
2. Dermoscopic structures associated with prognostic and therapeutic implications 295 
A few dermoscopic structures have been shown to have clinical and prognostic significance 296 
with structures associated with melanoma arising in a nevus,50,62 dermal invasion,56 Breslow 297 
>0.75mm,47, 57-59 mitotic activity,60, 61 or presence of lymph node metastases.62  Other 298 
dermoscopic features may also be relevant for therapeutic purposes as they are associated with 299 
genetic mutations targetable by specific therapies.12, 13, 15, 63 These findings are summarized in 300 
table II. 301 
 302 
Dermoscopic predictors of basal cell carcinoma subtype 303 
 Dermoscopy can be used to predict the most common subtypes of basal cell carcinomas 304 
(BCC): nodular and superficial. Lallas et al developed an algorithm in which the most relevant 305 
discriminator between superficial and non-superficial BCC was the presence of blue-ovoid nests 306 
(in the non-superficial subtypes).64 They also found arborizing vessels and ulceration to be 307 
associated with non-superficial BCC. Conversely, the presence of leaflike areas and serpentine 308 
vessels were associated with superficial BCC. Recently, Ahnlide et al. demonstrated that the 309 
presence of multiple small erosions in a flat lesion is predictive of superficial BCC in fair-310 
skinned individuals.14  311 
 312 
Thus, the findings more commonly associated with superficial BCC are serpentine 313 
vessels, multiple small erosions, flat surface and leaflike/spokewheel areas. The presence of 314 
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blue-ovoid nest, ulceration and arborizing vessels are more common in nodular BCC (figure 4, 315 
table III). This distinction can determine management since superficial BCC can potentially be 316 
treated non-surgically; streamlining the diagnostic and therapeutic process through a reduction in 317 
diagnostic biopsies. However, caution is advised since small foci of invasion cannot be excluded 318 
dermoscopically, and therefore other techniques such as reflectance confocal microscopy or 319 
optical coherence tomography can be used to identify deep tumor components.65-68 Interestingly, 320 
some dermoscopic findings have been described as therapeutic predictors. For example, the 321 
presence of ulceration in a non-treated BCC has been described to predict a good response to 322 
imquimod, regardless of subtype.69 323 
 324 
Dermoscopic predictors of the squamous cell carcinoma spectrum 325 
 The lesions included in the squamous cell carcinoma (SCC) spectrum share many 326 
dermoscopic features such as scale, rosettes and vessels. However, other dermoscopic features 327 
can aid in differentiating actinic keratosis, Bowen disease, well-differentiated SCC, and invasive 328 
SCC. The findings are summarized in table IV and shown in figure 5.   329 
 330 
  331 
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CONCLUSION 332 
In this CME series we have reviewed dermoscopic structures with their histopathology 333 
correlates and have shown that there exists an overlap between dermoscopy and histopathology. 334 
However, dermoscopy and histopathology are not equivalent. Histopathology holds an advantage 335 
over dermoscopy in that it evaluates vertical sections of tissue, which allows for the assessment 336 
of the full depth of the lesion from scanning magnification to cellular-level magnification. In 337 
addition, since histopathology is performed on paraffin-embedded tissue, it permits the use of 338 
immunohistochemical and molecular techniques to assist in diagnosis, which clearly cannot be 339 
done with dermoscopy. Conversely, unlike histology which evaluates less than 1% of the entire 340 
volume of the tumor, dermoscopy evaluates the entire surface area of the lesion in the horizontal 341 
plane, but only to the depth of the papillary dermis and not at cellular level resolution. The 342 
ability to evaluate the lesion in the horizontal plane permits the identification of certain 343 
diagnostically important structures, such as streaks, that are not commonly seen on vertical 344 
section histopathology. In addition, dermoscopy has the advantage of allowing the observer to 345 
identify colors, which may prove important in rendering a diagnosis. Other advantages of 346 
dermoscopy include the ability to evaluate the context of lesions on the skin and to monitor 347 
lesions over time to determine their biology and dynamics. 348 
 349 
Dermoscopy is an ideal tool to enhance the diagnosis of skin cancer and in fact has a high 350 
sensitivity for the diagnosis of skin cancers while retaining a high specificity, resulting in a low 351 
BMR. In addition, dermoscopy can identify areas within a tumor that have prognostic relevance 352 
for the pathologist when performing step sectioning. Therefore, dermoscopy can improve 353 
histologic diagnostic accuracy, reduce costs of histologic processing, and offer research 354 
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opportunities through informed sampling of specimens for genetic testing. However, an adequate 355 
knowledge of dermoscopy is required since exceptions occur. Nevertheless, dermoscopy can be a 356 
bridge between clinicians and pathologists that strengthens the clinical-pathological correlation. 357 
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-ABBREVIATIONS AND ACRONYMS:  570 
AK – Actinic Keratosis 571 
BCC – Basal Cell Carcinoma 572 
BMR – Benign to Malignant Ratio 573 
CME - Continuing Medical Education 574 
EVD – Ex Vivo Dermoscopy 575 
NEE – Naked-Eye Examination 576 
RCM – Reflectance Confocal Microscopy 577 
SCC - Squamous Cell Carcinoma 578 
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TABLES: 582 
Table I. Dermoscopic melanoma-specific structures and its odds ratio for melanoma 583 
Schematic illustration Metaphoric term Description Odds ratio for 
melanoma 
  
Atypical pigment 
network and 
angulated lines 
Network with increased variability in 
the color, thickness, distribution 
and/or spacing of the lines. When 
angulated, typically they show gray 
color 
2-922, 70-73 
 
 
Negative pigment 
network 
Serpiginous interconnecting 
broadened hypopigmented lines that 
surround elongated and curvilinear 
globules 
1.4-1.871, 74 
 
Irregular 
dots/globules 
Clods with variability in color, size, 
shape, or spacing and distributed in 
an asymmetric fashion 
1.7-4.822, 70, 75 
 
Irregular streaks 
(pseudopods and 
radial streaming) 
Radial lines with bulbous projections 
(pseudopods) or without (radial 
streaming) irregularly distributed 
1.5-5.822, 70-72, 
75
 
  
Granularity / 
peppering and 
scarlike 
depigmentation 
Granularity: blue-gray dots 
Scarlike depigmentation: white area 
lighter than surrounding skin devoid 
of vessels and shiny white structures 
2-18.370-72, 75 
 
Blue-whitish veil Homogenous white blue area 
overlying a raised area 1.74-13
70-72, 75
 
 
Shiny white 
streaks 
Short white lines oriented parallel 
and orthogonal to each other (only 
seen in polarized dermoscopy) 
2.5- 9.771, 76 
 
Irregular blotch One off-centered blotch or multiple blotches 1.88-4.1
22, 70-72
 
 
Polymorphous 
vessels 
Simultaneous presence of multiple 
types of vessels  2.0-3.04
22, 71, 72
 
Re-printed with permission of Ralph Braun and Ashfaq Marghoob (partial content in 584 
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Table II. Dermoscopic structures which have been shown to be predictors of histologic and 586 
genetic alterations when present in melanocytic lesions:  587 
Histologic/genetic association Dermoscopic predictors 
Melanoma arising in a nevus50,62 Negative pigment network 
Breslow depth >0.75 mm47, 57-59 
Blue-whitish veil 
Atypical Vessels 
Abrupt cutoff 
More than 4 colors 
Streaks 
Milky red areas 
More than 2 dermoscopic structures 
Dermal invasion56 Shiny white streaks 
Mitosis in thin (<1 mm) melanoma60 
Black color 
Peripheral streaks 
Mitosis and ulceration61 
Shiny white streaks 
Blue-whitish veil 
Milky-red areas 
Positive sentinel lymph node62 
Blotch 
Ulceration without a pigmented network 
Genetic 
mutations 
MAPK mutations (BRAF, NRAS)13 Peppering/granularity 
BRAF-mutated melanomas12, 15 
Irregular peripheral streaks 
Ulceration 
Blue-whitish veil 
BRAF wild-type melanomas12 Dotted vessels 
KIT mutations63 Dark homogeneous streaks 
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Table III. Dermoscopic structures associated with basal cell carcinoma subtypes:  588 
Basal cell carcinoma 
subtype 
Dermoscopic predictors Schematic 
Superficial basal cell 
carcinoma14, 64 
Flat surface 
 
Multiple small erosions 
 
Serpentine vessels 
 
Leaflike structures 
 
Non-superficial basal 
cell carcinoma64 
Blue ovoid nest 
 
Arborizing vessels 
 
Ulceration 
 
 589 
Re-printed with permission of Ralph Braun and Ashfaq Marghoob (partial content in 590 
Dermoscopedia.org). 591 
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Table IV. Dermoscopic structures associated with subtypes of squamous cell carcinoma 592 
subtypes. 593 
Histologic subtype Dermoscopic predictors Schematic 
Actinic keratosis77 
Strawberry pattern 
 
Bowen disease78 
Glomerular vessels 
 
Dark dots/globules or round 
circles in linear arrangement 
 
Well-differentiated 
squamous cell carcinoma77, 79 
White circles 
 
Looped vessels 
 
Poorly-differentiated 
squamous cell carcinoma80 
Vessels in >50% of the tumor 
surface 
 
Diffuse arrangement of vessels 
Bleeding 
 
 Re-printed with permission of Ralph Braun and Ashfaq Marghoob (partial content in 594 
Dermoscopedia.org). 595 
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-FIGURE LEGENDS:  596 
Fig 1. Evaluation of dermoscopic features on a formalin-fixed specimen (ex vivo dermoscopy) 597 
using a smartphone attached to a dermatoscope. 598 
 599 
Fig 2. Pigmented lesion showing an overall reticular pattern with an off-centered area of atypical 600 
blue and gray dots and globules (A, upper circle) and an area with scarlike depigmentation (A, 601 
lower circle). Histopathologically, the area with atypical globules revealed a higher degree of 602 
atypia (B) as opposed to the area depicting scarlike depigmentation on dermoscopy (C). Thus, 603 
dermoscopy can be useful in identifying the areas with higher degree of atypia. 604 
 605 
Fig 3. Dermoscopic images showing multiple melanoma-specific structures A, Melanoma arising 606 
in a nevus presenting with negative network (arrow) and irregular globules (arrowhead) B, 607 
Lentigo maligna depicting angulated lines (arrows) C, Invasive melanoma showing blue-whitish 608 
veil (asterisk), streaks (arrow) and irregular globules (arrowhead). D, Regressed melanoma 609 
presenting with atypical network (arrowheads), scarlike depigmentation and peppering (asterisk) 610 
and an irregular blotch (arrow). 611 
 612 
Fig 4. Dermoscopic images showing dermoscopic features associated with different basal cell 613 
subtypes A, Superficial basal cell carcinoma presenting with an erosion (asterisk), serpentine 614 
vessels (arrowhead) and leaflike areas (arrow) B, Nodular basal cell carcinoma presenting with 615 
an ulcer (asterisk), arborizing vessels (arrowhead) and blue ovoid nests (arrow). 616 
 617 
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Fig 5. Dermoscopic images showing dermoscopic features associated with different squamous 618 
cell subtypes A, Actinic keratosis presenting with an overall strawberry pattern B, Well-619 
differentiated squamous cell carcinoma presenting with central keratin plug (asterisk), looped 620 
vessels (arrow) and white circles (arrowhead) C, In situ squamous cell carcinoma depicting 621 
multiple linear black dots (arrowhead) D, Poorly-differentiated squamous cell carcinoma 622 
depicting diffuse polymorphous vessels (arrowheads) and scale (asterisk). 623 
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